Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2023-12-15 14:30:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company’s making these strides have incredible results to show...
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the r...
2023-12-12 14:59:53 ET More on Carmot Therapeutics Inc., Roche Holding, etc. Roche: Leveraging Nvidia's AI For Genentech's Innovation Carmot Therapeutics Begins U.S. IPO Rollout Be Patient, Roche Is A Clear Buy At This Price FDA puts partial clinical hold on ...
– Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas – – New data reinforce the potential of combination regimens in earlier treatment settings and add to the rob...
– Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favorable efficacy and safety profile of subcutaneous Hemlibra given soon after birth – – At nearly two years median follow-up in the descriptive, single-arm study, no babies e...
– Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone – – The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated wit...
– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – – Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in t...
2023-12-08 08:14:20 ET A multibillion-dollar deal in the healthcare industry helped lift the stock of a company, Viking Therapeutics (NASDAQ: VKTX) , not directly involved in the transaction. The deal centered around a hot class of drugs Viking is also developing. As a result, accor...
2023-12-06 13:46:53 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) added ~41% on Wednesday after the Massachusetts area biotech disclosed early data from a Phase 2 trial evaluating its oral leukemia drug, tamibarotene, as a combination therapy. Based on data from 19 pat...
2023-12-06 10:11:00 ET More on TG Therapeutics TG Therapeutics: Trying To Fill The Gap Back To $20 TG Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript TG Therapeutics: Q3 Earnings Spike Hard To Explain Given Rival's Numbers TG Therapeutics gains aft...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...